ValuEngine upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a hold rating to a buy rating in a research report released on Wednesday.

Other research analysts have also issued research reports about the stock. Citigroup raised shares of Endo International from a neutral rating to a buy rating and set a $11.00 price objective on the stock in a research note on Wednesday, June 27th. Cantor Fitzgerald set a $12.00 price target on shares of Endo International and gave the company a hold rating in a research note on Wednesday. Zacks Investment Research raised shares of Endo International from a strong sell rating to a hold rating in a research note on Tuesday, May 1st. Canaccord Genuity set a $13.00 price target on shares of Endo International and gave the company a hold rating in a research note on Wednesday, August 1st. Finally, Deutsche Bank set a $10.00 price target on shares of Endo International and gave the company a buy rating in a research note on Friday, June 1st. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $11.64.

Endo International stock traded down $0.18 during midday trading on Wednesday, hitting $15.65. 5,182,009 shares of the stock were exchanged, compared to its average volume of 5,123,331. Endo International has a 52 week low of $5.27 and a 52 week high of $17.34. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of 4.08, a PEG ratio of 6.47 and a beta of 0.49. The company has a debt-to-equity ratio of -132.64, a current ratio of 1.07 and a quick ratio of 0.88.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings data on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.22. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The business had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. During the same quarter last year, the firm earned $0.93 EPS. Endo International’s quarterly revenue was down 18.4% compared to the same quarter last year. analysts predict that Endo International will post 2.52 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Alps Advisors Inc. raised its holdings in shares of Endo International by 48.8% in the first quarter. Alps Advisors Inc. now owns 457,917 shares of the company’s stock valued at $2,720,000 after purchasing an additional 150,078 shares during the last quarter. Flinton Capital Management LLC raised its holdings in shares of Endo International by 84.2% in the first quarter. Flinton Capital Management LLC now owns 55,998 shares of the company’s stock valued at $333,000 after purchasing an additional 25,602 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Endo International by 518.7% in the first quarter. BNP Paribas Arbitrage SA now owns 3,293,567 shares of the company’s stock valued at $19,564,000 after purchasing an additional 2,761,216 shares during the last quarter. Schroder Investment Management Group raised its holdings in shares of Endo International by 529.4% in the first quarter. Schroder Investment Management Group now owns 419,796 shares of the company’s stock valued at $2,494,000 after purchasing an additional 353,096 shares during the last quarter. Finally, Neuburgh Advisers LLC raised its holdings in shares of Endo International by 84.2% in the first quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock valued at $215,000 after purchasing an additional 16,566 shares during the last quarter. Institutional investors own 96.27% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: NASDAQ

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.